PEDIATRICS · 2007 · 114 citations · 24 references
MedicineChild HealthPediatricsDevelopmental PediatricsInfant HealthNeonatologyGastroesophageal Reflux DiseaseGastroesophageal Reflux Disease CareInfant PharmacotherapyNeonatal DevelopmentNeonatal EpidemiologyNeonatal PharmacotherapyBirth Weight AssessmentGestational Age MeasurementMedication Safety In NewbornsNeonatal Medication Use EvaluationNeurodevelopmental EndpointsNeurodevelopmental FunctionNeurodevelopmental TrajectoriesPediatric Gastroesophageal Reflux Disease
The study aimed to quantify antireflux medication use at discharge in extremely low birth weight infants, identify associated risk factors, and evaluate its impact on growth and neurodevelopment at 18–22 months corrected age. A retrospective cohort of 1598 infants from NICHD Neonatal Research Network centers (2002–2003) was analyzed to determine factors linked to discharge with antireflux medication and subsequent growth or neurodevelopmental outcomes. Overall, 24.8% of infants received antireflux medication at discharge, with 47.6% of those discharged after 42 weeks postmenstrual age; use was associated with center, lower gestational age, and race but was not related to poorer growth or neurodevelopment at follow‑up.
Our goals were (1) to determine the use of medications to treat gastroesophageal reflux in extremely low birth weight infants (birth weight of < 1000 g) at discharge; (2) to identify risk factors associated with the use of medications to treat gastroesophageal reflux at discharge; and (3) to assess the contribution of gastroesophageal reflux medication use at discharge to growth and development at corrected ages of 18 to 22 months.This retrospective cohort analysis included extremely low birth weight infants enrolled at National Institute of Child Health and Human Development Neonatal Research Network Centers between 2002 and 2003 who survived to follow-up evaluations at corrected ages of 18 to 22 months. Analyses were used to identify factors associated with discharge with antireflux medications and poor growth or neurodevelopmental impairment after discharge.A total of 1598 infants were included in the analyses; 24.8% were discharged from the hospital with medications to treat gastroesophageal reflux. A total of 19.3% of the 1287 infants discharged at postmenstrual age of < or = 42 weeks were discharged with antireflux medications. For those infants, center, lower gestational age, and race had significant effects on the use of antireflux medications at discharge. A total of 47.6% of the 311 infants discharged at postmenstrual age of > 42 weeks were discharged with antireflux medications. For those infants, no tested variables were associated with treatment with antireflux medications at discharge. Use of antireflux medications at discharge was not associated with either poor growth or neurodevelopmental impairment at corrected ages of 18 to 22 months.Use of antireflux medications at the time of discharge seems to be common for extremely low birth weight infants, especially those discharged at postmenstrual age of > 42 weeks, but does not seem to have effects on growth or development at the time of follow-up evaluations.
24
CDC growth charts: United States.
Robert J. Kuczmarski, Cynthia L. Ogden, Laurence M. Grummer‐Strawn et al. · PubMed · 2000 · 5.2K citations